Men's Heath Market to Reach $4 Billion by 2016
This report focuses on men’s health therapeutics markets including the global erectile dysfunction therapeutics market, global male hypogonadism therapeutics market, and the global premature ejaculation (PE) therapeutics market.
Rockville, MD, September 24, 2010 --(PR.com)-- MarketResearch.com has announced the addition of GBI Research’s new report “Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market” to their collection of Therapeutic Area market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2794235.
The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, price, and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions, and licensing agreements that shape the global markets
In 2009, the global men’s health market was estimated to be worth $4,019m, representing a cumulative annual growth rate (CAGR) of 7.9% between 2001 and 2009, according to publisher GBI. By 2016, the global men’s health market is estimated to reach $5,509m, indicating a CAGR of 4.6% between 2009 and 2016. The major reason for the reduced growth rate is the patent expiry of a blockbuster drug.
This blockbuster drug is Viagra. The drug contributes significantly to the entire men’s health market. Hence, patent expiry of the drug will directly affect market growth, states the report.
The men’s health pipeline portfolio comprises me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth.
In addition, a steady increase in the prevalence population and in the prescription population will sustain the modest market growth during the forecast period.
According to the report, the men’s health pipeline portfolio has 51 projects across different developmental stages. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 68% of the total number of pipeline programs. In addition, the pipeline of two major markets, erectile dysfunction and male hypogonadism are holding 84% of the total pipeline molecules. This indicates that the launch of these drugs will boost the ED and male hypogonadism market.
The ED pipeline has five molecules in Phase III. Among these, avanafil, udenafil and TA-1790 are me-too molecules. These drugs are phosphodiesterase type 5 inhibitors and expected to be launched in the near future. Other, Phase III candidates such as Alfuzosin and Vitaros are first-in-class molecules. Launch of these molecules will again support the market growth.
The male hypogonadism pipeline has three molecules in each regulatory filing and Phase III stages. The premature ejaculation market also has three molecules in Phase III. The fact that the PE market does not have any FDA approved molecules, the introduction of new drugs will boost the market significantly.
For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2794235
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, price, and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions, and licensing agreements that shape the global markets
In 2009, the global men’s health market was estimated to be worth $4,019m, representing a cumulative annual growth rate (CAGR) of 7.9% between 2001 and 2009, according to publisher GBI. By 2016, the global men’s health market is estimated to reach $5,509m, indicating a CAGR of 4.6% between 2009 and 2016. The major reason for the reduced growth rate is the patent expiry of a blockbuster drug.
This blockbuster drug is Viagra. The drug contributes significantly to the entire men’s health market. Hence, patent expiry of the drug will directly affect market growth, states the report.
The men’s health pipeline portfolio comprises me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth.
In addition, a steady increase in the prevalence population and in the prescription population will sustain the modest market growth during the forecast period.
According to the report, the men’s health pipeline portfolio has 51 projects across different developmental stages. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 68% of the total number of pipeline programs. In addition, the pipeline of two major markets, erectile dysfunction and male hypogonadism are holding 84% of the total pipeline molecules. This indicates that the launch of these drugs will boost the ED and male hypogonadism market.
The ED pipeline has five molecules in Phase III. Among these, avanafil, udenafil and TA-1790 are me-too molecules. These drugs are phosphodiesterase type 5 inhibitors and expected to be launched in the near future. Other, Phase III candidates such as Alfuzosin and Vitaros are first-in-class molecules. Launch of these molecules will again support the market growth.
The male hypogonadism pipeline has three molecules in each regulatory filing and Phase III stages. The premature ejaculation market also has three molecules in Phase III. The fact that the PE market does not have any FDA approved molecules, the introduction of new drugs will boost the market significantly.
For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2794235
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
Contact
MarketResearch.com
Veronica Franco
240.747.3016
www.marketresearch.com/
Veronica Franco
240.747.3016
www.marketresearch.com/
Contact
Categories